Table 1.
Patient characteristics (newly diagnosed patients).
| Characteristics | |
|---|---|
| Total patients, n (%) | Number of patients, n (%) |
| Gender, n (%) | 58 (100%) |
| Female | 24 (41.4%) |
| Male | 34 (58.6%) |
| Median age at begin of induction, years (range) | 56.4 (35.0–71.8) |
| Type, n (%) | |
| IgG Kappa | 21 (36.2%) |
| IgG Lambda | 13 (22.4%) |
| IgA Kappa | 9 (15.5%) |
| IgA Lambda | 4 (6.9%) |
| IgD Lambda | 1 (1.7%) |
| BJP Kappa | 7 (12.1%) |
| BJP Lambda | 3 (5.2%) |
| Median initial β-2 microglobulin, mg/L (range) | 3.0 (1.6–226.0) |
| ISS at first diagnosis, n (%) | |
| I | 34 (58.6%) |
| II | 14 (24.1%) |
| III | 9 (15.5%) |
| n.a. | 1 (1.7%) |
| CRAB symptoms at first diagnosis, n (%) | |
| Hypercalcemia alone | 0 (0%) |
| Renal insufficiency | 2 (3.4%) |
| Anemia | 7 (12.1%) |
| Bone lesions | 39 (67.2%) |
| Hypercalcemia and bone lesions | 1 (1.7%) |
| Hypercalcemia, renal insufficiency and bone lesions | 1 (1.7%) |
| Renal insufficiency, anemia and bone lesions | 2 (3.4%) |
| Anemia and lytic bone lesions | |
| High-risk cytogenetics, n (%) | |
| del17p13 | 6 (10.3%) |
| t(4;14) | 4 (6.9%) |
| dupl 1q21 | 8 (13.8%) |
| del17p13 and t(4;14) | 3 (5.2%) |
| Induction therapy, n (%) | 1 (1.7%) |
| 3xPAd | 25 (43.1%) |
| 3xVCD | 33 (56.9%) |
| Number of autologous stem cell transplantation, n (%) | |
| 0 | 1 (1.7%) |
| 1 | 35 (60.3%) |
| 2 | 22 (37.9%) |
| Remission status before consolidation therapy, n (%) | |
| SD/MR | 1 (1.7%) |
| PR/VGPR | 24 (41.4%) |
| nCR/CR | 33 (56.9%) |
| Immune response, n (%) | |
| Positive | 19 (32.8%) |
| Negative | 15 (25.9%) |
| N.A. | 24 (41.4%) |
| Treatment with lenalidomide, n (%) | |
| no | 28 (48.3%) |
| yes | 30 (51.7%) |
| Median cumulative dose of lenalidomide, mg (range) | 2310 (525–8610) |
BJP, Bence–Jones protein; ISS, International Staging System; n.a., not available; del, deletion; t, translocation; dupl, duplication; SD, stable disease; MR, minor response; PR, partial response; VGPR, very good partial response; nCR, near complete remission; CR, complete remission; mg, milligram.